ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”),
an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in
multiple industries, today announced that it has entered into a
Memorandum of Understanding (MOU) with The South African Nuclear
Energy Corporation (Necsa) to collaborate on the research,
development and ultimately the commercial production of advanced
nuclear fuels.
Necsa is a state-owned company established by
the Republic of South Africa Nuclear Energy Act in 1999 with a
mandate to undertake and promote research and development in the
field of nuclear energy and radiation sciences. Necsa is also
responsible for processing source material, and co-operating with
other institutions on nuclear and related matters.
The proposed structure under discussion for the
delivery of the objectives of the MOU contemplates the formation of
a new entity in South Africa with a board of directors consisting
of at least two representatives from ASPI and Necsa. Discussions
between the parties during the last three years have focused on
advancing new nuclear fuel to cater especially for small modular
reactors as a start and eventually the construction of a nuclear
fuel facility for the production of HALEU.
It is anticipated that the research, development
and ultimate construction of a HALEU production facility will take
place at Pelindaba, which is situated approximately 22 miles west
of Pretoria, South Africa. Pelindaba is South Africa’s main nuclear
research center and is the home of the 20MW research nuclear
reactor, SAFARI-1, which over the last several years has become one
of the world’s largest suppliers of Molybdenum-99 and other
radioisotopes.
The MOU was signed at a signing ceremony that
took place at Pelindaba on November 14, 2024. Mr Paul Mann,
Chairman and CEO of ASP Isotopes, signed on behalf of ASP Isotopes
and Mr Loyiso Tyabashe, Group CEO of Necsa, signed on behalf of
Necsa. The signing ceremony was attended by representatives of the
South African Government and included the participation of Minister
Kgosientsho Ramokgopa, South Africa’s newly appointed Minister of
Electricity and Energy.
During the signing ceremony, Necsa GCEO, Mr
Loyiso Tyabashe remarked, “The memorandum signifies the commitment
of both Necsa and ASP Isotopes to bring essential nuclear fuels to
the world. It is particularly important for South Africa as nuclear
technology is set to take its rightful place in ensuring energy
security thus enabling economic growth, decarbonisation and
much-needed jobs. The MOU paves the way for Necsa to re-establish
its capability for nuclear fuel production and supply. I believe
that this collaboration will enhance the technological capabilities
of both parties and foster a long-lasting and mutually beneficial
partnership in the field of nuclear technology”
Paul Mann, Chairman and CEO of ASP Isotopes, and
Chairman and CEO of QLE commented that “Over the last several
decades, scientists at South Africa’s leading Universities and more
recently at ASP Isotopes have developed some of the world's most
advanced isotope enrichment technologies. Nuclear fuel has one of
the most severely compromised supply chains of any material in the
World. The World is in urgent need of additional suppliers. This
partnership with Necsa will enable us to accelerate the
construction of an advanced nuclear fuel facility.” He continued
“This proposed partnership with Necsa is designed to re-establish
South Africa as a leader in Nuclear Engineering producing the
advanced nuclear fuels that the world requires to prevent climate
change. It will also mobilize hundreds of workers in local regions
to build and operate the new manufacturing plant and support
thousands of direct and indirect jobs across a nationwide
manufacturing supply chain.”
ASPI recently entered into a Term Sheet with
TerraPower LLC which contemplates TerraPower providing funding for
the construction of a HALEU Facility and TerraPower purchasing
HALEU produced at the facility.
During the next 30 years, global energy
consumption will likely double(1). To meet 2050 climate goals, this
must occur with a zero increase in carbon emissions. The advanced
nuclear fuels required during the next 50 years are expected to
differ significantly from those used in the last 50 years.
Specifically, many small modular and advanced reactors in the
future are expected to require HALEU. The Company has received
interest from potential customers who collectively require over $37
billion of HALEU between the present day and 2037, at current
market prices(2).
The Company believes that its enrichment
technologies can be deployed in a new HALEU facility for
considerably lower capital costs, and in much less time, compared
to the construction of an enrichment facility using a traditional
centrifuge process. The Company has already constructed or is in
the process of constructing three isotope enrichment facilities in
South Africa. The first facility is expected to enrich Carbon-14
for use in healthcare and agrochemicals. The second facility is
expected to enrich Silicon-28, which the Company believes will
enable faster, more efficient semiconductors for use in artificial
intelligence and quantum computing. The third facility is expected
to enrich Ytterbium-176, a critically important raw material used
in the production of radio-oncology therapies.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage
advanced materials company dedicated to the development of
technology and processes to produce isotopes for use in multiple
industries. The Company employs proprietary technology, the
Aerodynamic Separation Process (“ASP technology”). The Company’s
initial focus is on producing and commercializing highly enriched
isotopes for the healthcare and technology industries. The Company
also plans to enrich isotopes for the nuclear energy sector using
Quantum Enrichment technology that the Company is developing. The
Company has isotope enrichment facilities in Pretoria, South
Africa, dedicated to the enrichment of isotopes of elements with a
low atomic mass (light isotopes).
There is a growing demand for isotopes such as
Silicon-28 for enabling quantum computing; Molybdenum-100,
Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new,
emerging healthcare applications, as well as Chlorine-37,
Lithium-6, Lithium-7 and Uranium-235 for green energy applications.
The ASP Technology (Aerodynamic Separation Process) is ideal for
enriching low and heavy atomic mass molecules. For more
information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including,
without limitation, statements relating to the the future of the
Company’s enrichment technologies as applied to uranium enrichment,
the outcome of the project contemplated by the MOU with Necsa, the
impact of ongoing economic uncertainty and geopolitical tensions
and risks on global supply chains, the market demand for enriched
uranium, the commencement of supply of enriched isotopes to
customers, and the construction of additional enrichment
facilities. Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy, and other future
conditions. Forward-looking statements can be identified by words
such as “believes,” “plans,” “anticipates,” “expects,” “estimates,”
“projects,” “will,” “may,” “might,” and words of a similar nature.
Examples of forward-looking statements include, among others but
are not limited to, statements we make regarding expected operating
results, such as future revenues and prospects from the potential
commercialization of isotopes, future performance under contracts,
and our strategies for product development, engaging with potential
customers, market position, and financial results. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict, many of which are outside our control.
Our actual results, financial condition, and events may differ
materially from those indicated in the forward-looking statements
based upon a number of factors. Forward-looking statements are not
a guarantee of future performance or developments. You are strongly
cautioned that reliance on any forward-looking statements involves
known and unknown risks and uncertainties. Therefore, you should
not rely on any of these forward-looking statements. There are many
important factors that could cause our actual results and financial
condition to differ materially from those indicated in the
forward-looking statements, including the outcomes of various
strategies and projects undertaken by the Company; the potential
impact of laws or government regulations or policies in South
Africa, the United Kingdom or elsewhere; our reliance on the
efforts of third parties; our ability to complete the construction
and commissioning of our enrichment plants or to commercialize
isotopes using the ASP technology or the Quantum Enrichment
Process; our ability to obtain regulatory approvals for the
production and distribution of isotopes; the financial terms of any
current and future commercial arrangements; our ability to complete
certain transactions and realize anticipated benefits from
acquisitions; contracts, dependence on our Intellectual Property
(IP) rights, certain IP rights of third parties; and the
competitive nature of our industry. Any forward-looking statement
made by us in this press release is based only on information
currently available to us and speaks only as of the date on which
it is made. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise. This press release includes
market and industry data and forecasts that we obtained from
internal research, publicly available information and industry
publications and surveys. Industry publications and surveys
generally state that the information contained therein has been
obtained from sources believed to be reliable. Unless otherwise
noted, statements as to our potential market position relative to
other companies are approximated and based on third-party data and
internal analysis and estimates as of the date of this press
release. We have not independently verified this information, and
it could prove inaccurate. Industry and market data could be wrong
because of the method by which sources obtained their data and
because information cannot always be verified with certainty due to
the limits on the availability and reliability of raw data, the
voluntary nature of the data-gathering process and other
limitations and uncertainties. In addition, we do not know all of
the assumptions regarding general economic conditions or growth
that were used in preparing the information and forecasts from
sources cited herein. No information in this press release should
be interpreted as an indication of future success, revenues,
results of operation, or stock price. All forward-looking
statements herein are qualified by reference to the cautionary
statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor
relationsEmail: Jassad@aspisotopes.comTelephone:
561-709-3043
- IEA. “Net Zero by 2050 – Analysis.” IEA,
www.iea.org/reports/net-zero-by-2050
- https://www.uxc.com/p/tools/FuelCalculator.aspx2021
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From Oct 2024 to Nov 2024
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From Nov 2023 to Nov 2024